1. Congenital myopathies
   Francesco Muntoni, United Kingdom
2. Inflammatory (radiculo)neuropathies
   Nortina Shahrizaila, Malaysia

1. Expected developments in the next two years
   Ingrid Tein, Canada

1. Ethics in pediatric neurology
   Bernard Dan, Belgium

1. Treatment of Pompe’s disease where are we now?
   Ans van der Ploeg, the Netherlands
2. Diagnosis and treatment of muscle channelopathies
   Francesco Muntoni, United Kingdom
3. Update on treatment of Duchenne muscular dystrophy
   Erik Niks, the Netherlands

Parallel expert session 2 – Movement disorders – treatment
Room: Auditorium

Chair: Jean-Pierre Lin, United Kingdom
Co-chair: Michèl Willemsen, the Netherlands

1. Deep Brain Stimulation
   Jean-Pierre Lin, United Kingdom
2. Phenotypes, genotypes and treatment of paroxysmal movement disorders
   Laura Silveira-Moriyama, Brazil
3. Clinical presentations, animal models and potential treatment of AADC
   Wang-Tso Lee, Taiwan, ROC

Parallel expert session 3 – Oncology
Room: Emerald Room

Chair: David Walker, United Kindom
Co-chair: Annemarie Fock, the Netherlands

1. Novel strategies for the treatment of pontine glioma?
   Dannis van Vuurden, the Netherlands
2. Strategies to minimise brain injury associated childhood brain tumour
   David Walker, United Kingdom
3. Late effects of cancer treatment
   Brice Fresneau, France

Parallel expert session 4 – Cerebral Palsy
Across the world
Room: Forum

Chair: Jeroen Vermeulen, the Netherlands
Co-chair: Stephen Back, U.S.A.

1. CP across the world care for handicapped children in resource rich countries
   Jeroen Vermeulen, the Netherlands
2. CP across the world bilirubin encephalopathy
   Arushi Saini, India
3. CP across the world care for handicapped children in Brazil
   Lucia Braga, Brazil

1. Genetic Diagnosis in Cerebral Palsy – Go for the cause
   Hilla Ben- Pazi, Israel
2. Evaluation of children with CP- Scales and Outcomes
   Hortensia Gimeno, United Kingdom
3. Neurophysiology and Neuropharmacolgy: what’s new on the horizon?
   Jonathan Mink, U.S.A.

ICNC focus lunch symposium 2 – Pyridoxine-Dependent Epilepsy: 2016 update on phenotype, diagnosis, treatment
Room: E104-E107

Chair: Clara van Karnebeek, Canada
Co-chair: Hans Hartmann, Germany

1. Evolving phenotype & neurodevelopmental outcomes
   Sidney Gospe, U.S.A.
2. Overview of biochemistry and genetics
   Emma Footitt, United Kingdom
3. Triple therapy to improve seizure control & neurodevelopment
   Clara van Karnebeek, Canada

ICNC focus lunch symposium 3 – Recent advances on striatal necrosis in childhood
Room: Emerald Room

Chair: Kling Chong, UK
Co-Chair: Russel Dale, Australia

1. Immune mediated basal ganglia injury
   Shekeeb Mohammed, Australia
2. Interferonopathies
   John Livingston, United Kingdom
3. Treatable causes of Leigh syndrome
   Belen Perez Duenas, Spain

Sponsored lunch symposium 4
(no part of the CME accreditation)
Room: Forum

1. Presentation a pilot study of the effects of selective Dorsal Rhizotomy in children with Severe Spastic Cerebral Palsy, GMFCS IV, at one year post-operatively
   Lucinda Carr, United Kingdom
2. Clinical profile of children with Cerebral Palsy born term compared to late- and post-term
   Russell Frank, Canada
3. Prediction of outcome using a new preterm white matter injury classification
   Miriam Martinez-Biarge, United Kingdom
4. Cerebral palsy (CP) in the Swedish national cohort of extremely preterm infants (EXPRESS); spectrum and co-morbidities
   Maria Hafström, Norway
5. Clinical and magnetic resonance imaging characteristics in children with Dyskinetic Cerebral Palsy due to Neonatal Hyperbilirubinemia- A developing country experience
   Arushi Gahlot Saini, India
6. Complementary and Alternative medicine use among children with chronic neurological disorders in Enugu, Nigeria
   Ngozi Ojinnaka, Nigeria
7. Mechanisms of transcranial direct-current stimulation (tDCS)-enhanced motor learning in healthy children
   Patrick Ciechanski, Canada

Parallel platform sessions 2 – Epilepsy – treatment and outcome 2
Room: Forum

Chair: Harry Chugani, U.S.A.
Co-chair: Hilde Braakman, the Netherlands

1. Evaluation of efficacy, safety and workload of inpatient and outpatient initiation of the Ketogenic Diet in children (0-18 y) with refractory epilepsy
   Elles van der Louw, the Netherlands
2. Efficacy and safety of Lacosamide in children
   Dipak Ram, United Kingdom
3. Addition of Pyridoxine to prednisolone in the treatment of infantile spasms: A randomized controlled trial
   Suvasini Sharma, India
4. Low-dose Add-on Fenfluramine in Dravet Syndrome: Effect on seizure control, sleep quality, and quality of Life in a prospective open-label study
   An-Sofie Schoonjans, Belgium
5. Efficacy of cannabidiol in refractory epilepsy in children and adolescents – prospective open label F/U registry of 45 patients
   Shay Menascu, Israel

Parallel platform sessions 3 – Movement disorders
Room: E104-E107

Chair: Wang-Tso Lee, Taiwan, ROC
Co-chair : Jolanda Schieving, the Netherlands

1. Diagnostic approach for pediatric patients with Dystonia
   Alfredo Cerisola, Uruguay
2. Psychiatric comorbidities in children with Dystonia
   Michelle Lorentzos, Australia
3. DNAJC6 mutations in childhood onset Parkinsonism-Dystonia
   Elisenda Cortes-Saladelafont, Spain
4. Segawa disease; clinical heterogeneity
   Yoshiko Nomura, Japan
5. The clinical spectrum of stereotypic movement disorders (SMD) in typically developing children and adolescents – a video and record review
   Michael Rotstein, Israel
6. GNAO1 – expanding a new phenotype – severe hyperkinetic movement disorder with episodic-life threatening exacerbations responsive to deep brain stimulation
   Michaela Waak, Australia
7. Delineation of the movement disorder spectrum in FOXG1-Related Disease
   Papandreou Apostolos, United Kingdom

Parallel platform sessions 4 – Neuromuscular disorders – treatment
Room: Emerald Room

Chair: Carsten Bonnemann, U.S.A.
Co-Chair: Jikke-Mien Niermeijer, the Netherlands

1. Ataluren confirmatory trial in DMD: Effect of Ataluren on activities of daily living in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
   Rosalie Quinlivan, United Kingdom
2. Results of North Star Ambulatory Assessments in the phase 3 ataluren confirmatory trial in patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD)
   Francesco Muntoni, United Kingdom
3. Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for Duchenne Muscular Dystrophy (DMD): Clinical update and longitudinal comparison to external controls on six-minute walk test (6MWT)
   Emily Naughton, U.S.A.
4. Development of a Prognostic Model for 1-year Change in 6-Minute Walk Distance (6MWD) in Patients with Duchenne Muscular Dystrophy (DMD)
   Nathalie Goemans, Belgium
5. Retrospective review of cause of death in Duchenne muscular dystrophy in the North East of England in the last 10 years
   Henriette van Ruiten, United Kingdom
6. Juvenile Myasthenia Gravis: Experience from a tertiary care centre
   Meenal Garg, India
7. Asymptomatic or oligosymptomatic hyperckemia in pediatric patients
   Eliana Cavassa, Argentina

Tour 1: Epilepsy 1
Tour 2: Epilepsy 2
Tour 3: Epilepsy 3
Tour 4: Epilepsy 4
Tour 5: Syndromes & Autism 1
Tour 6: Syndromes & Autism 2
Tour 7: Immune-mediated disorders
Tour 8: Miscellaneous 1
Tour 9: Miscellaneous 2
Tour 10: Neurometabolic disorders 1
Tour 11: Neurometabolic disorders 2
Tour 12:  Neuromuscular disorder
Tour 13: Stroke and vascular disorders
Tour 14: Cerebral Palsy 1
Tour 15: Cerebral Palsy 2
Tour 16: Movement disorders